In 2023, the import volume of antisera and other blood fractions to China stood at approximately 11.6 million kilograms. Forecasts indicate a steady year-on-year growth from 2024 to 2028, with values increasing from 12.053 million kilograms in 2024 to 13.904 million kilograms in 2028. This represents a Compound Annual Growth Rate (CAGR) of approximately 3.6% over the five-year forecast period. The consistent growth reflects the increasing demand for medical biological products in China.

Future trends to watch for include:

Advancements in biotechnology and personalized medicine potentially boosting demand.
Regulations impacting importation processes affecting overall market dynamics.
China’s domestic production capabilities of similar products and their effects on import needs.